Other notable investments in 2025 include Renasant Bio’s $54.5 million for kidney disease treatments, Nuclidium’s $99 million for radiopharmaceuticals, and Actithera’s $75.5 million for precision radioligand therapy.

The first half of 2025 saw a total of $26.6 billion raised across 238 funds, marking a near decade-low in venture capital fundraising, with the median fund closure taking 15.3 months, the longest in over ten years.

Hatteras Venture Partners celebrated a major milestone by closing over $200 million across two new healthcare funds, Hatteras Venture Partners VII and Hatteras Opportunity Fund I, marking their 25th anniversary and their 100th portfolio company investment.

This successful fundraising occurred despite a challenging environment for venture capital firms in 2025, highlighting Hatteras's strong position in the healthcare sector.

Based in Durham, North Carolina, Hatteras manages over $900 million through seven funds, focusing on early-stage investments in biotech, medical devices, and health tech, with notable companies like HistoSonics, Kymera Therapeutics, and G1 Therapeutics in its portfolio.

Additionally, Syntis Bio, an MIT spinout, closed $33 million to fund Phase 1 trials of an obesity treatment that creates a temporary intestinal lining to modulate nutrient absorption.

Varda Space Industries raised $187 million to manufacture drugs in space using microgravity, and Avalyn Pharma secured $100 million to develop inhaled therapies for pulmonary fibrosis.

Founded in 2000 with just under $3 million, Hatteras has grown significantly over 25 years, emphasizing its commitment to advancing healthcare innovation.

Recent biopharma financing highlights include Gameto’s $44 million Series C for reproductive therapies, Strand Therapeutics’ $153 million Series B for genetic medicines, and Minghui Pharmaceutical’s $131 million pre-IPO funding for cancer and dermatology assets.

Successful exits include companies like G1 Therapeutics, acquired for over $2 billion, and HistoSonics, which developed FDA-approved ultrasound technology for liver tumors and was sold for $2.25 billion, with other exits ranging from 7x returns to substantial acquisitions.

Funding rounds in 2025 also featured Chai Discovery’s $70 million Series A for AI-driven drug discovery, ARTBIO’s $132 million for radioligand therapies, and MapLight Therapeutics’ $372.5 million Series D targeting CNS disorders.

Hatteras’s leadership highlighted their 25-year journey of innovation, emphasizing their dedication to supporting transformative healthcare companies despite the ups and downs of the venture capital landscape.